Show simple item record

Ac-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application

dc.contributor.authorMarc Pretze
dc.contributor.authorFalk Kunkel
dc.contributor.authorRoswitha Runge
dc.contributor.authorRobert Freudenberg
dc.contributor.authorAnja Braune
dc.contributor.authorHolger Hartmann
dc.contributor.authorUwe Schwarz
dc.contributor.authorClaudia Brogsitter
dc.contributor.authorJörg Kotzerke
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherEckert & Ziegler Eurotope, 13125 Berlin, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherEckert & Ziegler Radiopharma, 38110 Braunschweig, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.contributor.otherDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
dc.date.accessioned2025-10-09T04:26:47Z
dc.date.available2025-10-09T04:26:47Z
dc.date.issued01-07-2021
dc.identifier.urihttps://www.mdpi.com/1424-8247/14/7/652
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40592
dc.description.abstractThe application of <sup>225</sup>Ac (half-life T<sub>1/2</sub> = 9.92 d) dramatically reduces the activity used for peptide receptor radionuclide therapy by a factor of 1000 in comparison to <sup>90</sup>Y, <sup>177</sup>Lu or <sup>188</sup>Re while maintaining the therapeutic outcome. Additionally, the range of alpha particles of <sup>225</sup>Ac and its daughter nuclides in tissue is much lower (47–85 μm for alpha energies E<sub>α</sub> = 5.8–8.4 MeV), which results in a very precise dose deposition within the tumor. DOTA-conjugated commercially available peptides used for endoradiotherapy, which can readily be labeled with <sup>177</sup>Lu or <sup>90</sup>Y, can also accommodate <sup>225</sup>Ac. The benefits are lower doses in normal tissue for the patient, dose reduction of the employees and environment and less shielding material. The low availability of <sup>225</sup>Ac activity is preventing its application in clinical practice. Overcoming this barrier would open a broad field of <sup>225</sup>Ac therapy. Independent which production pathway of <sup>225</sup>Ac proves the most feasible, the use of automated synthesis and feasible and reproducible patient doses are needed. The Modular-Lab EAZY is one example of a GMP-compliant system, and the cassettes used for synthesis are small. Therefore, also the waste after the synthesis can be minimized. In this work, two different automated setups with different purification systems are presented. In its final configuration, three masterbatches were performed on the ML EAZY for DOTA-TATE and PSMA-I&T, respectively, fulfilling all quality criteria with final radiochemical yields of 80–90% for the <sup>225</sup>Ac-labeled peptides.
dc.language.isoEN
dc.publisherMDPI AG
dc.subject.lccMedicine
dc.titleAc-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application
dc.typeArticle
dc.description.keywordsactinium-225
dc.description.keywordsTATE
dc.description.keywordsPSMA
dc.description.keywordsmodule synthesis
dc.description.keywordsendoradiotherapy
dc.description.keywordsGMP
dc.description.doi10.3390/ph14070652
dc.title.journalPharmaceuticals
dc.identifier.e-issn1424-8247
dc.identifier.oaioai:doaj.org/journal:9cc0c69b7c7547ec823b24ac1bd82ce7
dc.journal.infoVolume 14, Issue 7


This item appears in the following Collection(s)

Show simple item record